A comparative analysis of cytotoxic effects: Lactobacillus reuteri Extract vs. Newcastle Disease Virus in human colorectal cancer (HT-29 cell line)
Cancer Treatment and Research Communications · 2026
DOI: 10.1016/j.ctarc.2026.101294 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Ali Nemani Khiavi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Biology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Newcastle disease virus, Limosilactobacillus reuteri, Colorectal Neoplasms, Oncolytic Virotherapy. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Colorectal cancer (CRC) remains a major global health burden. Standard therapies, including surgical removal and chemotherapy, can cause significant complications such as fatigue and nausea. This research evaluated and compared the cell-killing effects of Lactobacillus reuteri extract and Newcastle disease virus on human CRC cells as potential lower-toxicity therapeutic options. MATERIALS AND METHODS: HT-29 cells were cultured under standard conditions and treated with different concentrations of Lactobacillus reuteri extract and Newcastle disease virus to determine IC50 values. Cell viability, apoptotic morphology, and caspase activity were evaluated using the MTT assay, acridine orange/propidium iodide staining, and caspase assay, respectively. Statistical significance was set at P< 0.05. RESULTS: Treatment with both compounds significantly reduced cell viability and enhanced apoptotic cell death in a manner related to dose and exposure time. Evaluation of caspase-8 and caspase-9 activities indicated that Newcastle disease virus triggered apoptosis via both death receptor-mediated and mitochondrial pathways, whereas Lactobacillus reuteri extract primarily activated the intrinsic apoptotic route. DISCUSSION: The present findings support the potential application of bacterial products and oncolytic viruses as adjuncts to conventional cancer therapies such as chemotherapy and radiotherapy, although clinical validation is still required. Their use may contribute to greater therapeutic efficacy and fewer side effects, thereby offering a potentially beneficial strategy in CRC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Biology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
- Department of Veterinary Medicine, Shab.C., Islamic Azad University, Shabestar, Iran.
- Applied Virology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
- Department of Aquatic Animal Health and Disease, Faculty of Veterinary Medicine, University of Tehran.
- Applied Virology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: aghayan.kiarash.20@gmail.com.
Zitieren
APA
Khiavi, A. N., Lahimchi, M. H., Fard, A. M., Heydari, M. R., & Aghayan, S. K. (2026). A comparative analysis of cytotoxic effects: Lactobacillus reuteri Extract vs. Newcastle Disease Virus in human colorectal cancer (HT-29 cell line). Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101294
Vancouver
Khiavi AN, Lahimchi MH, Fard AM, Heydari MR, Aghayan SK. A comparative analysis of cytotoxic effects: Lactobacillus reuteri Extract vs. Newcastle Disease Virus in human colorectal cancer (HT-29 cell line). Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2026.101294
BibTeX
@article{Khiavi2026,
author = {Khiavi, Ali Nemani and Lahimchi, Mohammad Hossein and Fard, Ashkan Mashaheri and Heydari, Mohammad Reza and Aghayan, Seyed Kiarash},
title = {A comparative analysis of cytotoxic effects: Lactobacillus reuteri Extract vs. Newcastle Disease Virus in human colorectal cancer (HT-29 cell line)},
journal = {Cancer Treatment and Research Communications},
year = {2026},
doi = {10.1016/j.ctarc.2026.101294}
}
EUVIMED